BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9679582)

  • 41. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences.
    Berrum-Svennung I; Granfors T; Jahnson S; Boman H; Holmäng S
    J Urol; 2008 Jan; 179(1):101-5; discussion 105-6. PubMed ID: 17997459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.
    Nomata K; Noguchi M; Kanetake H; Tsuda N; Hayashi M; Yamashita S; Sakuragi T; Kusaba Y; Shindo K;
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):266-70. PubMed ID: 12357299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized study of single early instillation of (2"R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma.
    Okamura K; Ono Y; Kinukawa T; Matsuura O; Yamada S; Ando T; Fukatsu T; Ohno Y; Ohshima S;
    Cancer; 2002 May; 94(9):2363-8. PubMed ID: 12015761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
    Hinotsu S; Akaza H; Ohashi Y; Kotake T
    Cancer; 1999 Nov; 86(9):1818-26. PubMed ID: 10547556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical efficacy of post-TUR prophylactic chemotherapy for superficial bladder cancer--the result of co-operative prospective randomized trial].
    Takahashi Y; Kuriyama M; Yamada S; Fujimoto Y; Takeuchi T; Doi T; Sakai S; Isogai K; Kanematsu M; Hayashi H; Fujihiro S; Hasegawa Y; Ehara H; Maeda S; Itoh F; Kobayashi S; Horie M; Matsuda S; Takeda A; Tei KH; Kawada Y
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1817-9. PubMed ID: 9382540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer].
    Kanayama H; Yokota K; Kurokawa Y; Kagawa S; Yokozeki H; Inai T; Ogawa I; Akazawa S; Hashimoto H; Mizuta K
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):651-5. PubMed ID: 10234296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG.
    Mugiya S; Ozono S; Nagata M; Takayama T; Ito T; Maruyama S; Hadano S; Nagae H
    Jpn J Clin Oncol; 2005 Jul; 35(7):395-9. PubMed ID: 15976065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
    Stoehr B; Mueller T; Granig T; Zangerl F; Steiner H
    BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.
    Berruti A; Mosca A; Bitossi R; Gorzegno G; Guercio S; Poggio M; Tampellini M; Porpiglia F; Ostellino O; Scarpa RM; Dogliotti L
    Anticancer Res; 2005; 25(6C):4475-9. PubMed ID: 16334129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci, E. Zini, N. Mondaini, v. Boddi, s. Mazzoli and R. Bartoletti J Urol 2008; 180: 110-115.
    Sylvester RJ; Oosterlinck W; O'Donnell M
    J Urol; 2009 Jan; 181(1):410. PubMed ID: 19010500
    [No Abstract]   [Full Text] [Related]  

  • 54. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
    Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
    J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the efficacy of single or double intravesical epirubicin instillation in the early postoperative period to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder: prospective, randomized multicenter study.
    Türkeri L; Tanıdır Y; Çal Ç; Özen H; Şahin H;
    Urol Int; 2010; 85(3):261-5. PubMed ID: 20332605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical study of bladder cancer: Proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy.
    Satoh A; Hanawa Y; Nakamura S
    Int J Urol; 2004 Jul; 11(7):476-82. PubMed ID: 15242355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer?
    Beltrami P; Ruggera L; Cazzoletti L; Schiavone D; Zattoni F
    Prostate; 2008 Aug; 68(11):1241-7. PubMed ID: 18484098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.